Verrica Pharmaceuticals Inc
| Fiscal year | Operating cash flow | Stock comp | Capex | Free cash flow | Net borrowing | FCFE | Shares (B) | FCF per share | Year-end price | FCF yield |
|---|---|---|---|---|---|---|---|---|---|---|
| 2019 | -0.0 | 0.0 | 0.0 | -0.0 | 0.0 | -0.0 | 0.00 | $-12.62 | $158.90 | -7.9% |
| 2020 | -0.0 | 0.0 | 0.0 | -0.0 | +0.0 | -0.0 | 0.00 | $-16.60 | $115.10 | -14.4% |
| 2021 | -0.0 | 0.0 | 0.0 | -0.0 | -0.0 | -0.1 | 0.00 | $-12.76 | $91.60 | -13.9% |
| 2022 | -0.0 | 0.0 | 0.0 | -0.0 | 0.0 | -0.0 | 0.00 | $-7.01 | $27.50 | -25.5% |
| 2023 | -0.0 | 0.0 | 0.0 | -0.1 | +0.0 | -0.0 | 0.00 | $-11.76 | $73.20 | -16.1% |
| 2024 | -0.1 | 0.0 | 0.0 | -0.1 | -0.0 | -0.1 | 0.01 | $-13.15 | $7.00 | -187.8% |
| 2025 | -0.0 | 0.0 | 0.0 | -0.0 | -0.0 | -0.1 | 0.01 | $-1.97 | $8.31 | -23.7% |
| 6-yr CAGR | n/m | -0.1% | n/m | n/m | n/a | n/m | 27.4% | n/m | -38.8% | avg -41.3% |
| Fiscal year | Revenue | EBITDA | EBITDA margin | Debt incl. leases | Cash & securities | Market cap | Enterprise value | EV / EBITDA | Net debt / EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| 2019 | 0.0 | -0.0 | n/m | 0.0 | 0.1 | 0 | 0 | n/m | n/m |
| 2020 | 0.0 | -0.0 | -332.9% | 0.0 | 0.1 | 0 | 0 | n/m | n/m |
| 2021 | 0.0 | -0.0 | -253.6% | 0.0 | 0.1 | 0 | 0 | n/m | n/m |
| 2022 | 0.0 | -0.0 | -227.8% | 0.0 | 0.0 | 0 | 0 | n/m | n/m |
| 2023 | 0.0 | -0.1 | -1,267.0% | 0.0 | 0.1 | 0 | 0 | n/m | n/m |
| 2024 | 0.0 | -0.1 | -854.5% | 0.0 | 0.0 | 0 | 0 | n/m | n/m |
| 2025 | 0.0 | -0.0 | -31.4% | 0.0 | 0.0 | 0 | 0 | n/m | n/m |
| 6-yr CAGR | n/m | n/m | avg -494.5% | 43.3% | -11.3% | -22.1% | -24.9% | median n/m | avg n/m |
Revenue grew n/m a year and EBITDA n/m a year from FY2019 to FY2025, and free cash flow after stock compensation did not grow from a positive base. The share count rose 27.4% a year, so per-share figures grew more slowly than the totals. The balance sheet carried more cash than debt in every one of those years.
From the data: EBITDA was not positive in enough years to set a growth rate and an exit multiple, so there is no hurdle price. The share count moved 26% in FY2022 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis. The share count moved 33% in FY2023 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis.
- Free cash flow is operating cash flow less stock-based compensation less capital spending. Stock comp is treated as a real cost.
- Net borrowing is the year's change in long-term debt. FCFE adds it back to free cash flow, the classic one-page definition.
- EBITDA is operating income plus depreciation and amortization. Debt includes lease obligations; cash includes short-term investments.
- Market cap uses the fiscal year-end price as traded, restated for later splits but not for dividends; enterprise value adds debt and subtracts cash.
- Share count is the yearly change in shares outstanding over the period; flat or falling clears. Cash margin is the latest free cash flow margin against its three-year average; within two points clears.
- Hurdle price is the present value, at the hurdle rate, of ten years of modeled free cash flow per share plus a year-10 sale at the exit multiple. It is shown as an exhibit: the 2011 to 2021 back-test found that buying below it did not sort winners from losers, so it is not scored.
- Cleared on a check means the number clears the stated rule; Not cleared means it does not. Durable, Holding and First year say how many fiscal years running the company has cleared all four staying-power checks (four or more, two or three, one); Partial and Not cleared count the checks it clears today. All of it is fact about the filings, not a rating of the stock.